Tags

Type your tag names separated by a space and hit enter

Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients.
Mult Scler. 2009 Jun; 15(6):721-7.MS

Abstract

BACKGROUND

Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-beta is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-beta on the other 20 members of the MMP family.

METHODS

This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-beta therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR.

RESULTS

RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time.

CONCLUSIONS

These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-beta in MS for at least 6 months.

Authors+Show Affiliations

Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19383643

Citation

Bernal, F, et al. "Regulation of Matrix Metalloproteinases and Their Inhibitors By Interferon-beta: a Longitudinal Study in Multiple Sclerosis Patients." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 15, no. 6, 2009, pp. 721-7.
Bernal F, Elias B, Hartung HP, et al. Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler. 2009;15(6):721-7.
Bernal, F., Elias, B., Hartung, H. P., & Kieseier, B. C. (2009). Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Multiple Sclerosis (Houndmills, Basingstoke, England), 15(6), 721-7. https://doi.org/10.1177/1352458509102920
Bernal F, et al. Regulation of Matrix Metalloproteinases and Their Inhibitors By Interferon-beta: a Longitudinal Study in Multiple Sclerosis Patients. Mult Scler. 2009;15(6):721-7. PubMed PMID: 19383643.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. AU - Bernal,F, AU - Elias,B, AU - Hartung,H P, AU - Kieseier,B C, Y1 - 2009/04/21/ PY - 2009/4/23/entrez PY - 2009/4/23/pubmed PY - 2009/8/22/medline SP - 721 EP - 7 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 15 IS - 6 N2 - BACKGROUND: Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-beta is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-beta on the other 20 members of the MMP family. METHODS: This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-beta therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR. RESULTS: RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time. CONCLUSIONS: These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-beta in MS for at least 6 months. SN - 1352-4585 UR - https://www.unboundmedicine.com/medline/citation/19383643/Regulation_of_matrix_metalloproteinases_and_their_inhibitors_by_interferon_beta:_a_longitudinal_study_in_multiple_sclerosis_patients_ L2 - https://journals.sagepub.com/doi/10.1177/1352458509102920?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -